Roswell Park Cancer Institute Physician Awarded Grant

BUFFALO, NY – Roswell Park Cancer Institute (RPCI) physician Roberto Pili, MD, has been awarded an R01 grant from the National Institutes of Health to study the role of histone deacetylase (HDAC) inhibitors in treating renal cell carcinoma (RCC). The two-year grant is for $675,000.

Dr. Pili is the principal investigator on a study with three goals: to further define the role of specific HDAC inhibitors; to evaluate novel combination strategies for targeted agents such as mammalian-target-of-rapamycin (mTOR), which are likely enhanced by use of HDAC inhibitors; and to conduct clinical studies with a combination of HDAC and mTOR inhibitors.

The study is expected to provide new insights on the role of HDACs in the renal tumor microenvironment, as well as early clinical evidence that combining HDAC inhibitors and molecular targeted inhibitors increases the antitumor effects. The study will also provide the foundation for future clinical trials in RCC patients.

Dr. Pili is Chief of the Genitourinary Section in the Department of Medicine and Co-Leader, of the Genitourinary Program at RPCI. He was named one of the Best Doctors® in America for 2009-2010.

Comments

Popular posts from this blog

Woman Charged with Posting
Nude Picture on Facebook

Arrests in Operation Diamond Drop

Two Arrested on Drug Charges